Fig. 2
From: Alternative splicing associated with cancer stemness in kidney renal clear cell carcinoma
Development and validation of the mRNA stemness indices (mRNAsi). a mRNAsi in PCBC stem cell signatures. Stem cell signatures including mRNAsi from endoderm (DE), embryoid bodies (EB), ectoderm (ECTO), mesothelioma (MESO) and stem cell (SC). b Stemness indices of the validation set derived using GSE30652 stemness signature. c Validation of mRNAsi in non-TCGA kidney cancer (KIRC) samples to define stemness status. Stratification of mRNAsi according to tissue types of GSE126964 samples (left) and different stage of GSE73731 samples (right). d Stratification of mRNAsi according to tissue types in TCGA KIRC samples. e-g mRNAsi from different tumor progressing (T\N\M stage) of KIRC were compared and showed in ecdf plot. Significance of difference among RCC subtypes were evaluated by Kruskal–Wallis test, P value < 0.01. h TCGA KIRC tumor types are ranked by mRNAsi; samples are divided into the top 10% samples that are similar to stem cells (TSC), and the middle 10–90% samples (MID), and the bottom 10% that are not similar to stem cells sample (USC). i The stemness indices for TSC and USC were correlated with known cancer biology clinical information, such as gender, smoking history and TNM stage